Literature DB >> 29947424

Basal-subtype bladder tumours show a 'hot' immunophenotype.

Anjelica Hodgson1,2, Stanley K Liu3, Danny Vesprini3, Bin Xu1,2, Michelle R Downes1,2.   

Abstract

AIMS: Basal and luminal molecular subgroups of muscle-invasive urothelial carcinoma (UC) can be recognised by the use of immunohistochemical markers. Studies have shown that responses to chemotherapy and outcomes differ among these subtypes. High-grade UC of the bladder is an immunogenic neoplasm that induces a substantial intratumoral and peritumoral immune response; the phenotype of infiltrating immune cells may yield prognostic information and predict response to therapy. In this study, we aimed to correlate the immunohistochemical phenotype of high-grade UC with immune microenvironment composition. METHODS AND
RESULTS: Two hundred and thirty-five cases of high-grade UC treated with cystectomy were reviewed. Clinicopathological variables for each case were recorded, and disease-free survival at last follow-up was calculated. Invasive front inflammation and tumour-infiltrating lymphocytes were scored for each case. Two hundred and seven cases were used to construct a triplicate-core tissue microarray (TMA), with sections stained for cytokeratin (CK) 5/6 and GATA3. Of the evaluable cases, 167 were designated as luminal (CK5/6- and GATA3+) and 29 as basal (CK5/6+ and GATA3-). Additional sequential TMA sections were stained for CD3, CD4, CD8, CD20, CD68, CD163, FOXP3, programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1) (SP263). Basal-subtype tumours showed a trend towards worse disease-specific survival (P = 0.078). There were statistically significant associations between basal subtype and CD8 expression (P = 0.008), PD-1 expression (P = 0.001), and PD-L1 expression (P = 0.014). Lower CD4/CD8 and increased CD8/FOXP3 ratios (P = 0.047 and P = 0.031, respectively) were also identified in the basal-subtype group.
CONCLUSIONS: Basal-subtype high-grade UC has an abundance of CD8+ T cells with increased expression of inhibitory markers, indicative of a 'hot' immunophenotype.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  PD-L1; immune cell typing; immune microenvironment; immunophenotype; urothelial carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29947424     DOI: 10.1111/his.13696

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  15 in total

1.  Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.

Authors:  Chung-Chieh Wang; Yu-Chieh Tsai; Yung-Ming Jeng
Journal:  PLoS One       Date:  2019-08-30       Impact factor: 3.240

2.  Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer.

Authors:  Giulio Eugenio Mandelli; Francesco Missale; Debora Bresciani; Luisa Benerini Gatta; Patrizia Scapini; Elena Caveggion; Elisa Roca; Mattia Bugatti; Matilde Monti; Luca Cristinelli; Sandra Belotti; Claudio Simeone; Stefano Calza; Laura Melocchi; William Vermi
Journal:  Cells       Date:  2020-01-25       Impact factor: 6.600

3.  PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype.

Authors:  Bohyun Kim; Cheol Lee; Young A Kim; Kyung Chul Moon
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

4.  Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma.

Authors:  Bohyun Kim; Insoon Jang; Kwangsoo Kim; Minsun Jung; Cheol Lee; Jeong Hwan Park; Young A Kim; Kyung Chul Moon
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

5.  Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.

Authors:  Anjelica Hodgson; Achim A Jungbluth; Nora Katabi; Bin Xu; Michelle R Downes
Journal:  Virchows Arch       Date:  2019-09-02       Impact factor: 4.064

Review 6.  [Molecular subtypes of urothelial carcinoma of the bladder-background and clinical relevance].

Authors:  Philipp Erben; Christoph Becker; Igor Tsaur; Matthias B Stope; Tilman Todenhöfer
Journal:  Urologe A       Date:  2021-01       Impact factor: 0.639

7.  Durvalumab activity in previously treated patients who stopped durvalumab without disease progression.

Authors:  Siddharth Sheth; Chen Gao; Nancy Mueller; Natasha Angra; Ashok Gupta; Caroline Germa; Pablo Martinez; Jean-Charles Soria
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

8.  Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).

Authors:  Sonja Bergmann; Anja Coym; Leonie Ott; Armin Soave; Michael Rink; Melanie Janning; Malgorzata Stoupiec; Cornelia Coith; Sven Peine; Gunhild von Amsberg; Klaus Pantel; Sabine Riethdorf
Journal:  Oncoimmunology       Date:  2020-03-23       Impact factor: 8.110

9.  Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma.

Authors:  Tzu-Hao Huang; Wei Cheng; Yeh-Han Wang
Journal:  Diagnostics (Basel)       Date:  2021-03-05

10.  Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer.

Authors:  Sandra van Wilpe; Mark A J Gorris; Lieke L van der Woude; Shabaz Sultan; Rutger H T Koornstra; Antoine G van der Heijden; Winald R Gerritsen; Michiel Simons; I Jolanda M de Vries; Niven Mehra
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.